Cargando…
Avidity of anti-phospholipid antibodies in relation to their levels
INTRODUCTION: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792445/ https://www.ncbi.nlm.nih.gov/pubmed/33456323 http://dx.doi.org/10.5114/ceji.2020.97901 |
_version_ | 1783633807848505344 |
---|---|
author | FIALOVÁ, LENKA KUCHAŘ, OLIVER PETRÁČKOVÁ, MILADA MALBOHAN, IVAN ZIMA, TOMÁŠ |
author_facet | FIALOVÁ, LENKA KUCHAŘ, OLIVER PETRÁČKOVÁ, MILADA MALBOHAN, IVAN ZIMA, TOMÁŠ |
author_sort | FIALOVÁ, LENKA |
collection | PubMed |
description | INTRODUCTION: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of their titres, from very low to high ones. MATERIAL AND METHODS: We analyzed 78 serum samples from 60 patients by ELISA with chaotropic agents, using urea concentration of 6 and 8 mol/l and single diluted serum samples. The changes of aCL levels and avidities were explored during a long-term follow-up in 14 patients. RESULTS: The avidities of aCLs did not differ in the groups of patients classified according to aCL levels. The higher avidity antibodies predominated in our patients and the fluctuation of avidities in the longitudinal follow-up did not show significant differences. No relationship between aCL levels and their avidities was found. CONCLUSIONS: aCL avidities seem to have no relationship with aCL levels and high-avidity aCLs; the potentially deleterious effects might be present also in patients with low and extremely low aCL levels. Avidity of aCLs belongs to stable characteristics with insignificant changes in time. |
format | Online Article Text |
id | pubmed-7792445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-77924452021-01-15 Avidity of anti-phospholipid antibodies in relation to their levels FIALOVÁ, LENKA KUCHAŘ, OLIVER PETRÁČKOVÁ, MILADA MALBOHAN, IVAN ZIMA, TOMÁŠ Cent Eur J Immunol Clinical Immunology INTRODUCTION: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of their titres, from very low to high ones. MATERIAL AND METHODS: We analyzed 78 serum samples from 60 patients by ELISA with chaotropic agents, using urea concentration of 6 and 8 mol/l and single diluted serum samples. The changes of aCL levels and avidities were explored during a long-term follow-up in 14 patients. RESULTS: The avidities of aCLs did not differ in the groups of patients classified according to aCL levels. The higher avidity antibodies predominated in our patients and the fluctuation of avidities in the longitudinal follow-up did not show significant differences. No relationship between aCL levels and their avidities was found. CONCLUSIONS: aCL avidities seem to have no relationship with aCL levels and high-avidity aCLs; the potentially deleterious effects might be present also in patients with low and extremely low aCL levels. Avidity of aCLs belongs to stable characteristics with insignificant changes in time. Termedia Publishing House 2020-07-27 2020 /pmc/articles/PMC7792445/ /pubmed/33456323 http://dx.doi.org/10.5114/ceji.2020.97901 Text en Copyright © 2020 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Clinical Immunology FIALOVÁ, LENKA KUCHAŘ, OLIVER PETRÁČKOVÁ, MILADA MALBOHAN, IVAN ZIMA, TOMÁŠ Avidity of anti-phospholipid antibodies in relation to their levels |
title | Avidity of anti-phospholipid antibodies in relation to their levels |
title_full | Avidity of anti-phospholipid antibodies in relation to their levels |
title_fullStr | Avidity of anti-phospholipid antibodies in relation to their levels |
title_full_unstemmed | Avidity of anti-phospholipid antibodies in relation to their levels |
title_short | Avidity of anti-phospholipid antibodies in relation to their levels |
title_sort | avidity of anti-phospholipid antibodies in relation to their levels |
topic | Clinical Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792445/ https://www.ncbi.nlm.nih.gov/pubmed/33456323 http://dx.doi.org/10.5114/ceji.2020.97901 |
work_keys_str_mv | AT fialovalenka avidityofantiphospholipidantibodiesinrelationtotheirlevels AT kucharoliver avidityofantiphospholipidantibodiesinrelationtotheirlevels AT petrackovamilada avidityofantiphospholipidantibodiesinrelationtotheirlevels AT malbohanivan avidityofantiphospholipidantibodiesinrelationtotheirlevels AT zimatomas avidityofantiphospholipidantibodiesinrelationtotheirlevels |